Buy & Sell Phillips 66 (PSX) – Phillips 66 Price Today
Aura AI Summary
Key Stats
- $71.41BMarket Cap
- EnergySector
- -17.28%3M Drawdown
- $93.38BEnterprise Value
- 2.85%Dividend Yield
- 74% Buy | 26% SellTrading Activity
- 62 daysTypical Hold Time
Phillips 66 (PSX) is currently valued at a market capitalization of $71.41B, with an enterprise value of $93.38B. Over the past 52 weeks, Phillips 66 has traded between a low of $118.37 and a high of $188.28, highlighting its annual price range. Over the past three months, Phillips 66 has recorded a drawdown of -17.28%, reflecting recent price volatility. Phillips 66 offers a dividend yield of 2.85%, with the most recent dividend of $1.27 paid on 18 May 26. On average, investors hold Phillips 66 for approximately 62 days, indicating typical investor behavior on the platform.
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Most Recent News
Fire engulfs Medline warehouse, causing inventory loss and short-term margin impact.
A fire destroyed Medline's 1 million-square-foot medical equipment warehouse in Tracy, California, affecting about 4% of its U.S. warehouse space. The blaze caused inventory losses and disrupted operations, creating short-term margin pressure as the ...

SpaceX prioritizes growth over profits, following Amazon's strategy to build future value.
SpaceX is choosing to focus on long-term growth rather than immediate profitability, similar to Amazon's approach in its early years. Experts say SpaceX could be profitable now if it reduced spending on projects like Starship and AI infrastructure, b...

New data show Lyell's ronde-cel CAR T-cell therapy is safe and effective for large B-cell lymphoma.
Lyell Immunopharma presented updated safety and translational data for its CAR T-cell therapy, ronde-cel, in treating relapsed or refractory large B-cell lymphoma (LBCL). Over 100 patients treated showed no severe cytokine release syndrome (CRS) and ...
